Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
Completed
Millennium Pharmaceuticals, Inc.
Phase 2
2007-12-01
This was an open-label study to provide an opportunity for participants with Ulcerative
Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve
participants with UC or Crohn's Disease (CD) to receive treatment with vedolizumab, and to
determine the long term safety of vedolizumab in patients afflicted with these diseases.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Completed
Millennium Pharmaceuticals, Inc.
Phase 3
2008-12-01
The primary purpose of this study was to determine the effect of vedolizumab induction
treatment on clinical response and remission at 6 weeks and to determine the effect of
vedolizumab maintenance treatment on clinical remission at 52 weeks.
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
Completed
Millennium Pharmaceuticals, Inc.
Phase 3
2009-01-01
The primary purpose of this study was to determine the effect of vedolizumab induction
treatment on clinical response at 6 weeks and to determine the effect of vedolizumab
maintenance treatment on clinical remission at 52 weeks.
Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis
Completed
Millennium Pharmaceuticals, Inc.
Phase 2
2007-05-01
The main objectives of this study were to evaluate the safety, tolerability, pharmacokinetics
(PK), and pharmacodynamics (PD) of multiple doses of vedolizumab in patients with ulcerative
colitis (UC).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
